Anthropic opened its virtual "Briefing: Enterprise Agents" event on Tuesday with a provocation. Kate Jensen, the company's head of Americas, told viewers that the hype around enterprise AI agents in ...

MILAN -- Following the departure of five TOP sponsors last year, the International Olympic Committee reported the lowest revenue for its global sponsorship program since 2020. Financial statements ...

The adoption rate of AI tools has skyrocketed in the programming world, enabling coders to generate vast amounts of code with simple text prompts. Earlier this year, Google found that 90 percent of ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

All critical vulnerabilities in Microsoft, third-party, and open source code are eligible for rewards if they impact Microsoft services. Microsoft on Thursday announced a massive expansion to its bug ...

Recently, a friend asked me a question that's been floating around every boardroom and business school: "With AI writing code, does programming still matter?" It's a fair question. Generative AI can ...

While cord-cutting has definitely had a major impact on the number of households with cable TV, there are still plenty of folks enjoying their favorite channels with coaxial and a set-top box. Cable ...

Abstract: In a typical introductory programming course, grading of student submitted programs is often done manually by examining the source code prior to assigning the final grade for reasons such as ...

Singapore-based no-code robotics startups Augmentus Pte. Ltd. announced today that it has raised $11 million in new funding. It will use the funds to accelerate deployment of its fully autonomous ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

Rallybio Corporation (NASDAQ:RLYB) agreed on Tuesday to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for hypophosphatasia (HPP), to joint venture partner Recursion ...